


CLAIMS

1. A compound of formula:



- 5 or a pharmaceutically acceptable salt thereof.

2. A medicament for use in the treatment of a respiratory tract disease, comprising the compound or the pharmaceutically acceptable salt of claim 1.

10

3. The medicament for use of claim 2, wherein the respiratory tract disease is rhinosinusitis.

4. The medicament for use of claim 2, wherein the
15 respiratory tract disease is caused by an RNA-comprising virus.

5. The medicament for use of claim 4, wherein the virus is selected from the group consisting of rhinovirus,
20 Cocksackie virus, respiratory syncytial virus, and influenza virus.

6. The medicament for use of claim 4 or 5, wherein the disease is exacerbations of asthma, chronic obstructive
25 pulmonary disease, bronchitis and mucoviscidosis, which are caused by rhinovirus, influenza virus and/or respiratory syncytial virus.

7. A pharmaceutical composition for use in the treatment of a respiratory tract disease, comprising an effective amount of the compound or the pharmaceutically acceptable salt of claim 1, and a pharmaceutically acceptable carrier.

8. The pharmaceutical composition for use of claim 7, wherein the respiratory tract disease is rhinosinusitis.

9. The pharmaceutical composition for use of claim 7, wherein the respiratory tract disease is caused by an RNA-comprising virus.

10. The pharmaceutical composition for use of claim 9, wherein the virus is selected from the group consisting of rhinovirus, Coxsackie virus, respiratory syncytial virus, and influenza virus.

11. The pharmaceutical composition for use of claim 7, wherein the disease is exacerbations of asthma, chronic obstructive pulmonary disease, bronchitis and mucoviscidosis, which are caused by rhinovirus, influenza virus and/or respiratory syncytial virus.

12. Use of the compound or the pharmaceutically acceptable salt of claim 1 in the manufacture of a medicament for the treatment of a respiratory tract disease.

13. The use of claim 12, wherein the respiratory tract disease is rhinosinusitis.


14. The use of claim 12, wherein the respiratory tract disease is caused by an RNA-comprising virus.

15. The use of claim 14, wherein the virus is selected from the group consisting of rhinovirus, Cocksackie virus, respiratory syncytial virus, and influenza virus.

5

16. The use of claim 12, wherein the disease is exacerbations of asthma, chronic obstructive pulmonary disease, bronchitis and mucoviscidosis, which are caused by rhinovirus, influenza virus and/or respiratory syncytial
10 virus.

17. A method for preparing a compound of formula



according to claim 1 or a pharmaceutically acceptable salt thereof, comprising heating of 2-(Imidazol-4-yl)-ethanamide
15 of pentandioic-1,5 acid with a dehydrating agent in an organic solvent.

18. The method of claim 17, wherein the dehydrating
20 agent is glutaric anhydride, and the method is performed under heating in an organic solvent.

19. The method of claim 18, wherein the organic solvent is dimethylformamide.

25

20. The method of claim 17, wherein the dehydrating agent is propionic anhydride, and the method is performed under heating in an organic solvent.

21. The method of claim 20, wherein the organic solvent is toluene.

22. The process of claim 20, wherein the method is
5 performed with addition of sodium acetate.

23. The method of claim 17, wherein the dehydrating agent is acetic anhydride, and the method is performed under heating in an organic solvent.
10

24. The method of claim 23, wherein the organic solvent is toluene.

25. The method of claim 17, wherein the dehydrating
15 agent is acetic acid chloroanhydride, and the method is performed under heating in an organic solvent.

26. The method of claim 25, wherein the organic solvent is acetic acid.
20

27. The method of claim 26, wherein the method is performed with addition of sodium acetate.

28. The method of claim 17, wherein the method is
25 performed at 90-120°C.

29. The method of claim 17, wherein the dehydrating agent is carbonyldiimidazole.